Community post

HYpharm GmbH and the German Center for Infection Research announced that their phage lysin HY-133 has entered phase I clinical trials. HY-133 aims to prevent nasal colonization by MRSA. The trial is conducted at the University Hospital of Tübingen to test the safety and toxicity of HY-133 in healthy volunteers.